IMGT Corp Ltd
456570
Company Profile
Business description
IMGT Corp Ltd develops a focused ultrasound-based drug delivery platform for intractable diseases. It is developing nanomedicines and focused ultrasound medical devices that respond to focused ultrasound. The firm has two pipeline products IMD20 and IMP101. IMD20 is a FUS device developed for chronic pain as a product with reduced size and output from IMD10 developed for cancer treatment. IMP101 is a nanoparticle used for hepatocarcinoma embolization.
Contact
172 Dolma-ro,
408, Healthcare Innovation Park
Bundang-gu, Gyeonggi-do
Seongnam-si13605
KORT: +82 319947077
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
35
Stocks News & Analysis
stocks
US utilities stocks keep rallying as investors bet on power demand growth
Rising electricity demand from data centers supports earnings growth, but Morningstar analysts say the sector looks less attractive after a sharp rally.
stocks
What did Morningstar subscribers buy and sell during March?
How the most traded shares in March stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.10 | 41.30 | -0.45% |
| CAC 40 | 8,268.65 | 32.67 | 0.40% |
| DAX 40 | 23,994.76 | 252.32 | 1.06% |
| Dow JONES (US) | 48,218.25 | 301.68 | 0.63% |
| FTSE 100 | 10,610.00 | 27.04 | 0.26% |
| HKSE | 25,903.67 | 242.82 | 0.95% |
| NASDAQ | 23,183.74 | 280.84 | 1.23% |
| Nikkei 225 | 57,877.39 | 1,374.62 | 2.43% |
| NZX 50 Index | 13,017.26 | 2.92 | -0.02% |
| S&P 500 | 6,886.24 | 69.35 | 1.02% |
| S&P/ASX 200 | 8,970.80 | 43.20 | -0.48% |
| SSE Composite Index | 4,026.63 | 38.07 | 0.95% |